These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review.
    Author: Hatala R, Dinh TT, Cook DJ.
    Journal: Clin Infect Dis; 1997 May; 24(5):810-5. PubMed ID: 9142773.
    Abstract:
    We examined the efficacy and toxicity of single daily dosing (SDD) of aminoglycosides for febrile, immunocompromised adults by systematically reviewing four randomized, controlled trials of SDD vs. standard dosing regimens. We assessed the methodological quality of each study and extracted data pertaining to efficacy and toxicity outcomes. Pooled risk ratios for the efficacy outcomes were bacteriologic cure, 1.00 (95% confidence interval [CI], 0.86-1.16); clinical cure, 0.97 (95% CI, 0.91-1.05); and mortality, 0.93 (95% CI, 0.62-1.41). The pooled nephrotoxicity risk ratio was 0.78 (95% CI, 0.31-1.94). Only one study assessed ototoxicity. Although our study was limited by the small number of trials available for review, the results suggest that SDD of aminoglycosides may be efficacious for febrile, immunocompromised patients. Additional studies are necessary for more precise quantification of the mortality and toxicity risk ratios.
    [Abstract] [Full Text] [Related] [New Search]